The Burden of Adverse Drug Reactions: Challenges and Opportunities

---

Authors

Amélie Zacharie¹ , Marion Mueller²

1. University of Freiburg
2. Novartis

Conference / event

Regulatory Affairs and Drug Development Master submission, July 2024 (Virtual)

Poster summary

This poster underscores the significant costs of adverse drug reactions (ADRs) for all stakeholders and emphasizes the need for collaboration and innovative solutions, such as real-world evidence, OMICS, and AI, to prevent and reduce the impact of ADRs.

Keywords

Adverse Drug Reaction, Pharmacovigilance, Real-world evidence, OMICS, AI, Health System

Research areas

Pharmacy and Pharmacology

References

1. Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-53. doi:10.1001/jama.2020.1166.
2. van der Hooft CS, Dieleman JP, Siemes C, Aarnoudse AJ, Verhamme KM, Stricker BH et al. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Saf. 2008;17(4):365-71. doi:10.1002/pds.1565.
3. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-9. doi:10.1136/bmj.329.7456.15.
4. Schurig AM, Bohme M, Just KS, Scholl C, Dormann H, Plank-Kiegele B et al. Adverse Drug Reactions (ADR) and Emergencies. Dtsch Arztebl Int. 2018;115(15):251-8. doi:10.3238/arztebl.2018.0251.
5. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med (2016) 375(23):2293-7. Epub 2016/12/14. doi: 10.1056/NEJMsb1609216.
6. Collins FS, Varmus H. A New Initiative on Precision Medicine. N Engl J Med (2015) 372(9):793-5. Epub 2015/01/31. doi: 10.1056/NEJMp1500523.
7. Topol EJ. High-Performance Medicine: The Convergence of Human and Artificial Intelligence. Nat Med (2019) 25(1):44-56. Epub 2019/01/09. doi: 10.1038/s41591-018-0300-7.

Funding

No data provided

Supplemental files

No data provided

Additional information

Competing interests

Marion Mueller is a full-time employee of Novartis Pharma AG and contributor to IMI ConcePTION, which is a public-private consortium funded by the European Government and the European Federation of Pharmaceutical Industry Associations. Amélie Zacharie has no competing interests.

Data availability statement

Data sharing not applicable to this poster as no datasets were generated or analyzed during the current study.

Creative Commons license

Copyright © 2024 Zacharie et al. This is an open access work distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.